Business
InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 13, 2018\n\n\n\nCSE: IN OTCQB: IMLFF\n\n\n\nVANCOUVER, March 13, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the appointment of Eric Hsu, Ph.D., as Vice President of Preclinical Research and Development.  In this capacity, Dr. Hsu will assume primary responsibility for advancing the Company's cannabinoid biosynthesis manufacturing process and preclinical research on new drug candidates, including INM-085 for glaucoma and INM-405 for pain.\n\n\n \n \n\n \nDr. Hsu joins InMed with over 18 years of scientific leadership experience in developing novel gene transfer technologies and validation of preclinical drug candidates. Prior to joining InMed, Dr. Hsu held various positions with enGene Inc., including VP of Research and VP of Scientific Affairs and Operations. During his tenure, his responsibilities covered a wide array of activities, from benchtop research, formulation development and manufacturing process development to patent prosecution, vendor contract negotiations and execution, and research partnerships. He has co-authored over 25 publications and abstracts and holds five patents. Dr. Hsu received his Ph.D. from the University of Toronto in Medical Biophysics.  \n\nEric A. Adams, InMed's President & CEO, commented, \"Dr. Hsu brings a tremendous scope and depth of scientific leadership to our Company. He has extensive experience to face several specific challenges which we will encounter as we develop our technologies, including biosynthesis and new product candidates.\"  \n\n\"InMed's impressive technologies and focused approach to drug discovery and development have resulted in an exciting pipeline of drug candidates across many disease areas\", stated Dr. Hsu. \"I am very excited to j...